Dr. Caroline Lehmann is a PhD biologist by training with a focus on immunology and virology. From 2016 to 2023 she was responsible for deal flow management and investment support at EMBL Ventures, a venture capital firm associated with the European Molecular Biology Laboratory (www.embl.de). During her time at EMBL Ventures she also consulted with life-science start-up’s with a focus on strategy and business models. Before that she was clinical project manager at Vakzine Projekt Management GmbH (Hannover) where she managed international vaccination- and oncology clinical trials. In her free time, she enjoys time with her family and plays tennis.